Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus Aureus

Last updated: April 2, 2022
Sponsor: Medical University of Lublin
Overall Status: Completed

Phase

3

Condition

Acute Rhinitis

Allergy

Allergies & Asthma

Treatment

N/A

Clinical Study ID

NCT04637425
KE-0254/41/2018(2)
  • Ages 5-17
  • All Genders

Study Summary

This study assesses the effectiveness of Polyvalent Mechanical Bacterial Lysate (PMBL-Ismigen) in reducing nasal methicillin-resistant Staphylococcus aureus (MRSA) colony growth in children with pollen allergic rhinitis (AR) aged 5 to 17. Half of the participants received PMBL and the other half received a placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children of both genders aged 5 to 17 years.
  • Children with grass pollen-induced allergic rhinitis recognized and treated accordingto current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations.
  • Positive skin prick test to grass pollen allergens or positive specific IgE (definedas ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens.
  • Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasalcongestion, nasal itching, sneezing) in at least two recent grass pollen seasons inPoland before inclusion in the study.
  • Proper use of polyvalent mechanical bacterial lysate sublingual tablets.
  • Written informed consent obtained from parents/guardians before any study relatedprocedures are performed.

Exclusion

Exclusion Criteria:

  • Patient received mechanical or any other polyvalent bacterial lysate immunostimulationwithin the previous 12 months before randomisation visit.
  • Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 yearsbefore the start of the study.
  • Vaccination performed within 3 months before the beginning of the study.
  • Deficiencies in cellular and humoral immunity.
  • Treatment with antibiotics within the last 1 month before the start of the study.
  • Treatment with systemic corticosteroids within the last 6 months before the start ofthe study.
  • Pregnant or breastfeeding woman.
  • Other chronic conditions of the nose or nasal sinuses.

Study Design

Total Participants: 70
Study Start date:
April 22, 2018
Estimated Completion Date:
August 31, 2020

Study Description

Seasonal allergic rhinitis (SAR) is caused by the allergens of wind-pollinated plants, and in Poland mainly by grass pollen allergens. During the grass pollen season, patients may suffer from fatigue, weakness, lack of fitness, difficulty in sleeping and reduced performance at school. In people allergic to the above-mentioned pollen, the disease significantly reduces the quality of life and requires intensive treatment in the pollen period.

MRSA colonizing the nasal cavity has the ability to actively modulate the immune response in children suffering from SAR. Many studies have shown a greater severity of AR symptoms in patients with a MRSA-positive nasal swab compared to patients with normal nasal flora.

Due to the high incidence of AR, the negative impact of the disease on the quality of life, and incomplete effectiveness of previously available therapeutic methods, new methods of treatment are being developed. Recent research highlights the immunoregulatory potential of bacterial lysates, indicating the possibility of their future use in the prevention and treatment of allergic diseases, including atopic dermatitis, AR, and asthma.

Based on the above considerations, it can be hypothesized that bacterial lysates reduce the severity of AR symptoms by eradicating MRSA from the nasal cavity. However, so far no randomized, double-blind, placebo-controlled study has been conducted to evaluate the effect of bacterial lysates on nasal Staphylococcus aureus carriage in children with SAR.

The main aim of this study was to evaluate nasal colonization by MRSA among children with SAR and the effect of PMBL on the reduction of MRSA colony growth in these children.

70 children with SAR were enrolled to this study and were randomly assigned to the PMBL group (n=35) and placebo group (n=35). Two visits took place as part of the study: at the beginning of the grass pollen season and at the end of the season. The time frame of the grass pollen season for south-eastern Poland was determined using the "95%" method on the basis of measurements of grass pollen concentration in the atmospheric air, which were obtained from the Environmental Allergy Research Centre in Warsaw. Nasal swabs for bacteriological cultures were taken at each visit and were transferred to the hospital laboratory.

Connect with a study center

  • Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin

    Lublin, 20-093
    Poland

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.